Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board

Heinrich, Kathrin; Miller-Phillips, Lisa; Ziemann, Frank; Hasselmann, Korbinian; Rühlmann, Katharina; Flach, Madeleine; Biro, Dorottya; Bergwelt-Baildon, Michael von; Holch, Julian; Herold, Tobias; Baumgarten, Louisa von; Greif, Philip A. ; Jeremias, Irmela; Wuerstlein, Rachel; Casuscelli, Jozefina; Spitzweg, Christine; Seidensticker, Max; Renz, Bernhard; Corradini, Stefanie; Baumeister, Philipp; Goni, Elisabetta; Tufman, Amanda; Jung, Andreas; Kumbrink, Jörg; Kirchner, Thomas; Klauschen, Frederick; Metzeler, Klaus H.; Heinemann, Volker und Westphalen, C. Benedikt (2022): Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board. In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 5: S. 1905-1915

Abstract

Purpose In 2016, the University of Munich Molecular Tumor Board (MTB) was implemented to initiate a precision oncology program. This review of cases was conducted to assess clinical implications and functionality of the program, to identify current limitations and to inform future directions of these efforts. Methods Charts, molecular profiles, and tumor board decisions of the first 1000 consecutive cases (01/2016-03/2020) were reviewed. Descriptive statistics were applied to describe relevant findings. Results Of the first 1000 patients presented to the MTB;914 patients received comprehensive genomic profiling. Median age of patients was 56 years and 58% were female. The most prevalent diagnoses were breast (16%) and colorectal cancer (10%). Different types of targeted or genome-wide sequencing assays were used;most of them offered by the local department of pathology. Testing was technically successful in 88%. In 41% of cases, a genomic alteration triggered a therapeutic recommendation. The fraction of patients receiving a tumor board recommendation differed significantly between malignancies ranging from over 50% in breast or biliary tract to less than 30% in pancreatic cancers. Based on a retrospective chart review, 17% of patients with an MTB recommendation received appropriate treatment. Conclusion Based on these retrospective analyses, patients with certain malignancies (breast and biliary tract cancer) tend to be more likely to have actionable variants. The low rate of therapeutic implementation (17% of patients receiving a tumor board recommendation) underscores the importance of meticulous follow-up for these patients and ensuring broad access to innovative therapies for patients receiving molecular tumor profiling.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0171-5216
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 491502892